





Amoxicillin/Clavulanate Oral Suspension (7:1 concentration)

<u>The Issue:</u> NH pharmacy is <u>adding</u> amoxicillin/clavulanate 7:1 concentration oral suspension to inventory for indications that require high amoxicillin dosing while staying under the maximum daily clavulanate dose (12.5 mg/kg/day). This is something that the currently stocked 4:1 concentration cannot provide without exceeding the maximum daily clavulanate dose.

Clinical Use:

- broad spectrum beta lactam antibiotic for treatment of infections cause by susceptible bacteria
- 7:1 concentration of the oral suspension is used for infections requiring high amoxicillin dosing such as acute otitis media and invasive infections including pneumonia

Practice Implications:

- Clinicians should be aware of this new product availability in NH.
- Clinicians should follow dosing, administration instructions, and other information for amoxicillin/clavulanate oral suspension provided in the BC Children's Hospital (BCCH) Drug Formulary (see pedmed online).
- <u>*PRESCRIBER NOTE*</u>: In alignment with BCCH standards, NH prescribers must indicate the formulation required on each order for amoxicillin/clavulanate oral suspension (4:1 or 7:1).

Product Availability and Comparison:

Availability of 4:1 and 7:1 suspensions may vary in the coming months due to drug shortages. Local pharmacies will provide supply of whatever is available at the time.

• 4:1 formulation:

- > tablet (amoxicillin/clavulanate): 500/125 mg
- suspension (amoxicillin/clavulanate): 25/6.25 mg/mL and 50/12.5 mg/mL

• 7:1 formulation:

- > tablet: 875/125 mg
- suspension: 40/5.7 mg/mL and 80/11.4 mg/mL

November 25, 2022	Drug Shortage		For further information contact:
For the information of	Drug Discontinuation		Medication Use Management Pharmacists
physicians, nurses, and pharmacists.	New Drug Product	✓	, and the second
PLEASE POST	Best Practice		mumpharmacist@northernhealth.ca